Date: 2015-10-28
Type of information: Licensing agreement
Compound: MyoScreen™
Company: Cytoo (France) Daiichi Sankyo (Japan)
Therapeutic area: Neuromuscular diseases
Type agreement: licensing
Action mechanism: MyoScreen™ is a physiological human skeletal muscle in vitro model for drug screening, compatible with High Content Screening. It is based on fully mature human skeletal muscle (from human donors). MyoScreen™ can be used to develop disease models for metabolic and neuromuscular disorders drug discovery programs. The multiplexed image analysis opens up new avenues for the classification of drugs\' mechanism of action.
Disease:
Details: * On October 28, 2015, Cytoo announces that Daiichi Sankyo has selected the company\'s in vitro muscle platform MyoScreen™ to develop a novel cell-based assay and screen drug candidates on a key mechanism involved in several muscular diseases.
MyoScreen™ is a high throughput and high content screening platform that enables the identification and characterization of new compounds that affect muscle hypertrophy, contractility, metabolism and muscular diseases. The system thus meets the broad requirements of the pharmaceutical, nutraceutical and animal health industries aiming ultimately to discover new active ingredients.
Created in 2008, Cytoo is specialized in the development of physiologically-relevant cellular models and assays for High Content Screening (HCS). The company has developed its own models of human striated muscle (MyoScreen™) and skin (EpiScreen™, FibroScreen™) available to the pharmaceutical, dermato-cosmetic, nutraceutical, food processing and animal health sectors for screening of biologically active compounds. Independently, the enterprise has engaged in its own drug discovery business committed to treating muscle wasting and Duchenne muscular dystrophy.
Financial terms: Financial terms of this agreement are not disclosed.
Latest news:
